Abstract MHC class II-derived recombinant T cell receptor ligands (RTLs) modulate the behavior of pathogenic T cells and can reverse clinical and histological signs of autoimmune disease in experimental autoimmune encephalomyelitis (EAE), experimental autoimmune uveitis (EAU) and collagen-induced arthritis (CIA), and are currently in clinical trials for treatment of multiple sclerosis (MS). To expand the utility of these rationally-designed biologics and explore their mechanism(s) of activity in vivo, we have engineered RTL constructs bearing cysteine-tethered antigenic peptides and demonstrate that the appropriate cysteine-tethered RTLs effectively treat EAE. The data presented here suggests that the mechanism by which antigen-specific tolerance induction by RTLs bearing cysteine-tethered antigenic peptides in vivo involves delivery of RTL/antigen to endosomal compartments for processing and re-presentation by full-length MHC class II, with RTLs bearing cysteine-tethered antigenic peptides requiring gamma-interferon-inducible lysosomal thiol-reductase (GILT) for therapeutic activity.
Introduction
We have previously described recombinant TCR ligands (RTLs) derived from the beta-1 and alpha-1 domains of MHC class II molecules bearing covalently-tethered Ags (Burrows et al. 1998 (Burrows et al. , 1999 Chang et al. 2001) . These molecules effectively tolerize Ag-specific CD4+ T cells (Fontenot et al. 2006; Huan et al. 2008) and are being used as molecular tools for probing the earliest TCR signal transduction events in T cells Wang et al. 2003; Burrows et al. 2001 ) and for dissecting the processing of antigens within the endosomal compartments of antigen presenting cells Offner et al. 2011) . MHC class II molecules present 9-15 aa peptides with amino-& carboxy-termini that can extend outside of the peptide binding groove, and we have previously described work that takes advantage of these features by engineering MHC class II-derived RTLs bearing genetically encoded peptide antigens as amino-terminal extensions of the recombinant molecules, with the covalently-tethered peptides folding back into the peptide binding groove . While this strategy has proven extremely useful for developing tolerogenic RTLs bearing peptide antigens that consist of only the 20 naturally occurring amino acids, we sought to develop methods for covalently tethering peptide antigens that cannot be genetically encoded within the DNA sequence of the vectors used for expressing the recombinant molecules, such as peptide antigens that contain posttranslational modifications (PTMs). Here we present data documenting the utility of cysteine chemistry to covalently tether peptide antigens to recombinant b1a1 MHC class II molecules. The beta-1 domains of all MHC class II molecules have a conserved C17-C81 disulfide bond (IA b -derived RTL550 numbering). Peptide antigens with single cysteine substitutions in the P4 anchor position can be efficiently covalently tethered to recombinant MHC class II molecules by inserting into the conserved beta-1 domain disulfide bond under appropriate conditions. Cysteinetethered MOG-35-55 recombinant I-A b (RTL550-Cys-MOG-35-55) effectively treated experimental autoimmune encephalomyelitis (EAE) in WT C57BL/6 mice, but could not treat EAE in gamma-interferon-inducible lysosomal thiol-reductase (GILT) KO mice. The data presented here suggests that the mechanism by which antigen-specific tolerance induction by RTLs bearing cysteine-tethered antigenic peptides in vivo involves delivery of RTL/antigen to endosomal compartments for processing and re-presentation by full-length MHC class II, with RTLs bearing cysteinetethered antigenic peptides requiring GILT for therapeutic activity.
Methods
Design, expression, purification & biophysical characterization of recombinant MHC molecules General methods for the design, cloning and expression of recombinant b1 and a1 domains of MHC molecules, termed recombinant T cell receptor ligands (RTLs), have been previously described (Burrows et al. 1999; Chang et al. 2001; Huan et al. 2005; Fontenot et al. 2006) .
Redox capture conditions Reactions (10:1 peptide:protein molar ratio) were incubated at 37°C for 60 h, with I-A bderived RTL550, 200 ug/ml in 100 mM NaPO 4 , pH 6.5, 150 mM NaCl, 0.05% SDS, 0.01% NaN 3 . For sample analysis 20 μl aliquots at various time points were mixed with an equal volume of a 2X electrophoresis sample buffer (1% glycerol. 500 mM Tris, 0.2% SDS and bromophenol blue at pH 8.0). Samples were then placed on ice for 30 min, heated at 90°C for 6 min +/− β-mercaptoethanol and separated by 10-20% SDS-PAGE followed by coomassie blue staining to visualize the proteins. Proteins were quantified by densitometry scanning using BioRad's Molecular Imager FX and Quantity One software.
Animals C57BL/6 male mice were obtained from Jackson Laboratories at 7-8 weeks of age. Gamma interferoninducible lysosomal thiol reductase knockout (GILT KO) animals on the C57BL/6 background were obtained from Dr. Peter Cresswell, Yale University/Howard Hughes Medical Institute (New Haven CT). C57BL/6 and GILT KO mice were housed in the Animal Resource Facility at the Portland Veterans Affairs Medical Center (Portland, OR, USA) in accordance with institutional guidelines. The study was conducted in accordance with National Institutes of Health guidelines for the use of experimental animals, and the protocols were approved by the Institutional Animal Care and Use Committee.
Antigens Synthetic mouse MOG (mMOG) (MEVG-WYRPPFSRVVHLYRNGK) as well as shortened and cysteine-substituted variants were synthesized by Genescript, Inc., (Piscataway, NJ, USA).
Induction of active EAE and treatment with RTL550-Cys-MOG Mice immunized with mMOG-35-55 peptide received 200 μg of mMOG-35-55 peptide in an equal volume of CFA containing 4 mg/ml heat-killed Mycobacterium tuberculosis (MTb). All mice were also injected with 75 and 200 ng pertussis toxin (Ptx) intraperitoneally on days 0 and 2 relative to immunization. The mice were assessed for signs of EAE according to the following scale: 0, normal; 1, limp tail or mild hind limb weakness; 2, moderate hind limb weakness or mild ataxia; 3, moderately severe hind limb weakness; 4, severe hind limb weakness or mild forelimb weakness or moderate ataxia; 5, paraplegia with no more than moderate forelimb weakness; and 6, paraplegia with severe forelimb weakness or severe ataxia or moribund condition. At the onset of clinical signs of EAE (days 10-13 when the clinical scores were ≥1.5), mice were divided into two groups and treated with 100 μl of 1 mg/ml RTL550; "empty"), RTL551 bearing genetically encoded mMOG-35-55, or RTL550-Cys-MOG-35-55, i.v. for 5 consecutive days. Mice were monitored for changes in disease score until they were euthanized for ex vivo analyses. Statistical differences between disease scores of vehicle, RTL550, RTL551 and RTL550-Cys-MOG-35-55 treatment groups were determined by Mann-Whitney U test.
Results
The design and characterization of human DR-, DP-& DQ-, murine I-A b -& I-A s -, and Lewis rat RT1.B-derived single chain constructs consisting of the β1 and α1 domains of the heterodimeric MHC class II molecules expressed as single polypeptide chains has been previously described Fontenot et al. 2006; Burrows et al. 1999) . These molecules are referred to as recombinant T cell receptor ligands (RTLs). "Empty" RTL550 derived from murine I-A b (RTL550; RTL550-series) efficiently captured MOG-35-55 (S42C) peptide (Fig. 1 ).
RTL550-Cys-MOG-35-55 (S42C) treats EAE in WT C57BL/ 6 but not GILT KO mice Treatment of WT C57BL/6 EAE male mice with vehicle, RTL551 or 550-Cys-MOG-35-55 (S42C) was initiated at onset of clinical signs of disease followed by 4 additional daily injections. RTL551 has the MOG-35-55 peptide genetically engineered into the expression construct, with the Ag peptide linked at the amino-terminus of the primary sequence of the molecule (Fig. 1a) . In RTL550-Cys-MOG-35-55 (S42C) the peptide is cysteine-tethered to the RTL550 "empty" construct. Clinical scores of EAE in WT C57BL/6 mice are shown in Fig. 2 . EAE progression was completely halted in the mice as early as one treatment with RTL551 or RTL550-Cys-MOG-35-55 (S42C), and both treatment groups had significantly reduced clinical disease scores at all the time points as compared to the vehicle alone control group of mice which showed a worsening of disease score over time, with similar clinical efficacy of both RTL551 bearing genetically encoded MOG-35-55, or RTL550 with cysteine-tethered MOG-35-55 (S42C) (Fig. 2) . We used gamma-interferon-inducible lysosomal thiol-reductase (GILT) KO mice to examine how important processing and representation of Ag peptide is for the therapeutic efficacy of the compounds. We have previously demonstrated that RTLs bearing antigenic peptides as amino-terminal extensions are processed with the antigenic peptide re-presented in the context of full-length MHC class II (Dahan et al. 2011) . Proteins that are internalized and processed by antigen processing cells (APCs) for presentation of MHC class II-restricted peptide antigens to CD4+ T cells frequently contain disulfide bonds, and their reduction in the endocytic pathway facilitates processing and access to peptides that would otherwise be inaccessible for MHC class II loading. GILT is constitutively expressed in The disulfidetethered RTL550/peptide complex migrates as a higher molecular weight species (~31 kD) than the "empty" RTL550. Samples under reducing (Red) and non-reducing (NR) conditions as indicated late endocytic compartments of APCs and it has been shown to be a prerequisite for presentation of particular antigenic peptides (Maric et al. 2001; Sealy et al. 2008; Norton and Haque 2009; Bogunovic et al. 2010) . While RTL551 was effective in treating GILT KO mice as seen from the cumulative disease index (CDI) of 39±1 for untreated GILT KO mice vs. 19±5 for GILT KO treated with RTL551 (p≤0.05). In contrast, the cysteinetethered RTL550-Cys-MOG-35-55 (S42C) did not treat the GILT KO mice (Fig. 3) , suggesting that GILT is required for therapeutic efficacy of the cysteine-tethered, but not the genetically-encoded antigen constructs. The data presented here suggests that at least part of the mechanism for tolerance induction in vivo is receptor-mediated delivery of RTLs bearing MOG-35-55 to endosomal compartments for processing and re-presentation by full-length MHC class II, and that in the absence of GILT, reduction and re-presentation of cysteinetethered peptide does not occur.
Discussion
Here we present data demonstrating that cysteine-tethered RTL550-Cys-MOG effectively treats EAE. Testing of cysteine-tethered IA b -derived RTLs in the C57BL/6 MOGinduced EAE model allowed us to test the broader applicability of the RTL approach to treatment of autoimmunity involving antigens that cannot be simply encoded into the primary sequence of the recombinant molecule, and our data support the therapeutic efficacy of cysteine-tethered RTL550-Cys-MOG-35-55 (S42C) as being equivalent to RTL551 bearing genetically encoded MOG-35-55 in wild-type mice (Fig. 2) . The use of GILT KO mice on the same background allowed us to gauge the importance of processing & re-presentation of the cysteinetethered MOG-35-55 peptide. While RTL551 was effective in treating GILT KO mice, the cysteine-tethered RTL550-Cys-MOG-35-55 (S42C) did not treat the GILT KO mice (Fig. 3) . This suggests that GILT is required for therapeutic efficacy of the cysteine-tethered, but not the genetically-encoded antigen constructs, and helps clarify the multiple potential in vivo mechanism of RTL therapy. Previous studies using RTLs bearing genetically encoded cognate or non-cognate peptide antigen documented that RTLs bind directly to cognate TCR with low avidity in vitro (McMahan et al. 2003) . Signal transduction studies using T cell hybridomas and primary human T cell lines further documented that RTLs bind directly to the TCR, with RTL in vitro serving as partial TCR agonists and triggering specific downstream signaling events that deplete intracellular calcium stores without fully activating T cells and without triggering an influx of extracellular calcium (Wang et al. 2003) . The potent clinical efficacy of RTLs in various animal disease models led to the successful initiation of a Phase I clinical trial for human HLA-DR2-derived RTLs for treatment of multiple sclerosis, which we have recently successfully completed Vijayshree Yadav et al. 2012) . As part of these clinical trials, pharmacokinetic analysis of DR2-derived RTL bearing genetically encoded MOG-35- Fig. 2 RTL-550-Cys-MOG-35-55 (S42P) treats EAE. Male C57BL/6 mice were immunized with MOG-35-55/CFA/Ptx. Mice were scored for clinical signs of EAE as outlined in Materials and Methods. EAE mice treated with RTL-550-Cys-MOG-35-55 (S42P) at onset had significantly reduced clinical scores as compared to vehicle treated mice. Data presented are the mean ± SD disease scores of 14-15 mice per group. Significant differences between the groups daily mean EAE score were determined using Mann Whitney U test. Cumulative Disease Index was determined by student's T test 55 (RTL1000) was performed on a subset of patients. This study revealed a dose-dependent increase in exposure and a short half-life in blood plasma of~5 min for subjects receiving RTL1000 (Vijayshree Yadav et al. 2012 ). The rapid half-life and clearance values and the high non-physiological volume of distribution suggested that RTL1000 binds to cellular components in blood. Consistent with these observations, preclinical studies in mice demonstrated a half-life of~10 min (unpublished data). RTL551 binding to mouse APCs was shown to inhibit T-cell activation and transfer of EAE , and RTL1000 binding to human platelets reduced platelet aggregation and prolonged occlusive thrombus formation in blood (Itakura et al. 2010) . Taken together these findings suggest that RTLs bind to a high affinity receptor distinct from the TCR on T cells, enabling both antigenspecific and more general mechanisms for modulating autoimmune disease and neuroinflammation. We have recently identified and characterized this high affinity receptor on CD11b + cells (Vandenbark et al. 2012) . Our data is consistent with an in vivo model of therapeutic efficacy that includes 1) cell-surface-bound RTLs interacting directly with TCR on cognate T cells, 2) direct modulation of CD11b + cells toward a tolerogenic phenotype, and, based on the work presented here, 3) receptor-mediated delivery of RTLs bearing antigen to endosomal compartments for processing and re-presentation by full-length MHC class II, delivering an antigen-specific tolerogenic signal to cognate T cells. The data presented here suggests that the efficacy of RTLs bearing cysteine-tethered antigen requires GILT, because RTL550-Cys-MOG-35-55 S42C does not treat EAE in GILT KO mice (Fig. 3) .
The chemistry involved in constructing RTLs with cysteinetethered antigenic peptides is a straightforward approach toward expanding the practical utility of RTL treatment of autoimmune disease to situations that cannot be accomplished using RTLs bearing genetically encoded peptide antigens. We have previously described the utility of conventional RTL therapy to collagen-induced arthritis, myelin basic protein (MBP) induced EAE and uveitis using genetically encoded collagen or MBP peptides (Huan et al. 2008; Burrows et al. 2000; Adamus et al. 2006) . While successful in the experimental setting, in both rheumatoid arthritis (RA) and human multiple sclerosis (MS) there is evidence for pathology driven by T cells that recognize peptides bearing PTMs (Cantaert et al. 2006; Quirke et al. 2011; Moscarello et al. 2007 ). In human RA, a key target of the aberrant immune response are proteins that have undergone PTM by citrullination, an inflammationdriven process that is thought to break immune tolerance because T cells that recognize the citrullinated epitopes generated in the joints as a result of inflammation are not expressed in the thymus and are thus deleted during lymphocyte selection (Vossenaar et al. 2004; Chapuy-Regaud et al. 2005; Makrygiannakis et al. 2006; Cantaert et al. 2006; Quirke et al. 2011) . Similarly, citrillination of MBP has been suggested to play an important role in the pathology of multiple sclerosis, with six sites on human MBP citrullinated in pathological settings, with the change of the positively charged arginine to neutral citrulline compromising the ability of MBP to interact with the lipid bilayer (Moscarello et al. 2007 ). These post-translational modifications occur during inflammation and cell death and cannot simply be genetically encoded into the RTLs. The chemistry described here provides a practical solution to this problem and is currently being used to develop DR4-and DR2-derived cysteine-tethered peptide constructs to test their efficacy for targeted tolerance induction in models of disease that involve citrillinated epitopes.
